Biomea Fusion (NASDAQ:BMEA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research note issued to investors on Thursday morning,Benzinga reports. D. Boral Capital currently has a $16.00 price objective on the stock.

Several other equities analysts have also issued reports on the stock. HC Wainwright cut their price objective on shares of Biomea Fusion from $40.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Oppenheimer set a $10.00 price target on Biomea Fusion in a report on Monday, March 24th. Finally, Barclays decreased their price objective on Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 2nd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $22.60.

Biomea Fusion Trading Down 2.1%

Shares of BMEA stock opened at $1.43 on Thursday. The company has a 50 day simple moving average of $2.07 and a two-hundred day simple moving average of $4.04. The stock has a market cap of $53.73 million, a P/E ratio of -0.36 and a beta of -0.07. Biomea Fusion has a 12 month low of $1.38 and a 12 month high of $13.43.

Biomea Fusion (NASDAQ:BMEA) last posted its earnings results on Monday, May 5th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.04. As a group, equities analysts forecast that Biomea Fusion will post -3.93 earnings per share for the current year.

Institutional Investors Weigh In On Biomea Fusion

A number of large investors have recently modified their holdings of the business. CWM LLC boosted its stake in Biomea Fusion by 8,058.5% in the 1st quarter. CWM LLC now owns 16,888 shares of the company’s stock worth $36,000 after purchasing an additional 16,681 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Biomea Fusion during the first quarter valued at $37,000. Bayesian Capital Management LP acquired a new position in shares of Biomea Fusion in the 4th quarter valued at $42,000. Wells Fargo & Company MN raised its stake in Biomea Fusion by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock worth $50,000 after acquiring an additional 4,399 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Biomea Fusion in the 4th quarter worth $54,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.